Krystal Biotech initiated at Cantor Fitzgerald

Krystal Biotech initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Elemer Piros initiated Krystal Biotech with an Overweight and $28 price target Piros said Kyrstal is developing off-the-shelf dermatological gene therapy treatments for severe monogenic diseases and expansion into chronic skin conditions, and believes shares are positioned well well ahead of Q4 interim clinical data.
https://thefly.com/landingPageNews.php?id=2788189